CyberKnife Ultra-hypofractionated SBRT for Localized PROStatE cancEr - Trial NCT06331013
Access comprehensive clinical trial information for NCT06331013 through Pure Global AI's free database. This phase not specified trial is sponsored by European Institute of Oncology and is currently Recruiting. The study focuses on Prostate Cancer. Target enrollment is 60 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
European Institute of Oncology
Timeline & Enrollment
N/A
Feb 20, 2023
Dec 31, 2029
Primary Outcome
Number of Participants with Acute GU and GI toxicities (RTOG),Number of Participants with Late GU and GI toxicities (RTOG),Evaluation of patient-reported toxicity,Evaluation of patient-reported quality of life
Summary
This is a prospective observational study. The study will proceed with the enrollment of 60
 patients in 2 years. he aim of the present study is to evaluate effectiveness of
 ultra-hypofractionated (UH) CyberKnife Stereotactic Body Radiation Therapy treatment on the
 whole prostate gland plus Simultaneous integrated boost (SIB) to the dominant intraprostatic
 lesions (DIL(s) in intermediate-unfavourable to high-risk Prostate Cancer (PCa) patients.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06331013
Non-Device Trial